1. Pink Sheet
  2. >>Geography
  3. >>Europe
  4. >>United Kingdom

Janssen Secures Only Partial Win In Appeal Against English Funding Snub For Spravato

 
• By Neena Brizmohun

Of the nine specific appeal points raised against NICE’s rejection of the company’s antidepressant nasal spray, Spravato, just one was upheld.

depression cartoon 2100803380 1200.jpg
There is an unmet need for effective treatment options for treatment-resistant depression in England • Source: Shutterstock

England’s health technology assessment institute NICE failed to act fairly when it rejected Janssen’s depression nasal spray, Spravato (esketamine), because it did not explain fully how the uncertainties in the evidence were taken into account in its decision making, an independent appeal panel has ruled.

NICE’s appraisal committee is to reconvene next month to address this point, although it is not obliged to change the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United Kingdom

More from Europe

EU Pharma Reform: Lawyers Unpack Diverging Visions For Innovation

 
• By Eliza Slawther

There are now three draft versions of the legislative text that will overhaul the framework governing pharmaceuticals in the EU. Lawyers explain how the approaches proposed by the European Commission, European Parliament and Council of the EU differ and highlight implications for industry.

‘Prices Can Remain Contaminated Indefinitely’: Advanz Brushed Aside On UK Liothyronine Appeal

 
• By Dean Rudge

England’s Court of Appeal has upheld a Competition Appeal Tribunal’s 2023 finding that Advanz and its former owner Cinven abused their dominant position in the UK market for liothyronine tablets by charging prices that were many orders of magnitude higher than the benchmark for fair pricing.

New EU Filings

 
• By Neena Brizmohun

Linerixibat, GSK's treatment for cholestatic pruritus in patients with primary biliary cholangitis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.